A nonrandomized controlled clinical trial showed that the IL‐6 inhibitor tocilizumab could significantly reduce oxygen consumption, imaging abnormalities, and clinical prognosis in patients with COVID‐19.32 This evidence concerns the gene IL6 and COVID-19.